Rui Bernardino, R. Sayyid, Ricardo Leão, A. Zlotta, T. H. van der Kwast, Laurence Klotz, N. Fleshner
{"title":"对格里森 7（3+4）型前列腺癌采用主动监测：叙述性综述","authors":"Rui Bernardino, R. Sayyid, Ricardo Leão, A. Zlotta, T. H. van der Kwast, Laurence Klotz, N. Fleshner","doi":"10.5489/cuaj.8539","DOIUrl":null,"url":null,"abstract":"The interest in broadening the application of active surveillance (AS) has been increasing, encompassing patients who may not strictly adhere to the conventional criteria for low-risk prostate cancer (PCa), particularly those diagnosed with small-volume Gleason grade group 2 disease. Nonetheless, accurately identifying individuals with low-intermediate risk PCa who can safely undergo AS without facing disease progression remains a challenge. This review aims to delve into the progression of this evolving trend specifically within this cohort of men, while also examining strategies aimed at minimizing irreversible disease advancement. Additionally, we address the criteria for patient selection, recommended followup schedules, and the indicators prompting intervention.","PeriodicalId":38001,"journal":{"name":"Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review\",\"authors\":\"Rui Bernardino, R. Sayyid, Ricardo Leão, A. Zlotta, T. H. van der Kwast, Laurence Klotz, N. Fleshner\",\"doi\":\"10.5489/cuaj.8539\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The interest in broadening the application of active surveillance (AS) has been increasing, encompassing patients who may not strictly adhere to the conventional criteria for low-risk prostate cancer (PCa), particularly those diagnosed with small-volume Gleason grade group 2 disease. Nonetheless, accurately identifying individuals with low-intermediate risk PCa who can safely undergo AS without facing disease progression remains a challenge. This review aims to delve into the progression of this evolving trend specifically within this cohort of men, while also examining strategies aimed at minimizing irreversible disease advancement. Additionally, we address the criteria for patient selection, recommended followup schedules, and the indicators prompting intervention.\",\"PeriodicalId\":38001,\"journal\":{\"name\":\"Canadian Urological Association Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Urological Association Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5489/cuaj.8539\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Urological Association Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5489/cuaj.8539","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
人们对扩大主动监测（AS）应用范围的兴趣与日俱增，这包括那些可能并不严格遵守低危前列腺癌（PCa）传统标准的患者，尤其是那些被诊断出患有小体积格里森2级疾病的患者。尽管如此，准确识别哪些中低危 PCa 患者可以安全地接受 AS 治疗而不会面临疾病进展仍是一项挑战。本综述旨在深入探讨这一不断发展的趋势在这一男性群体中的具体进展情况，同时研究旨在最大限度地减少不可逆疾病进展的策略。此外，我们还探讨了选择患者的标准、推荐的随访时间表以及提示干预的指标。
Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review
The interest in broadening the application of active surveillance (AS) has been increasing, encompassing patients who may not strictly adhere to the conventional criteria for low-risk prostate cancer (PCa), particularly those diagnosed with small-volume Gleason grade group 2 disease. Nonetheless, accurately identifying individuals with low-intermediate risk PCa who can safely undergo AS without facing disease progression remains a challenge. This review aims to delve into the progression of this evolving trend specifically within this cohort of men, while also examining strategies aimed at minimizing irreversible disease advancement. Additionally, we address the criteria for patient selection, recommended followup schedules, and the indicators prompting intervention.
期刊介绍：
Published by the Canadian Urological Association, the Canadian Urological Association Journal (CUAJ) released its first issue in March 2007, and was published four times that year under the guidance of founding editor (Editor Emeritus as of 2012), Dr. Laurence H. Klotz. In 2008, CUAJ became a bimonthly publication. As of 2013, articles have been published monthly, alternating between print and online-only versions (print issues are available in February, April, June, August, October, and December; online-only issues are produced in January, March, May, July, September, and November). In 2017, the journal launched an ahead-of-print publishing strategy, in which accepted manuscripts are published electronically on our website and cited on PubMed ahead of their official issue-based publication date. By significantly shortening the time to article availability, we offer our readers more flexibility in the way they engage with our content: as a continuous stream, or in a monthly “package,” or both. CUAJ covers a broad range of urological topics — oncology, pediatrics, transplantation, endourology, female urology, infertility, and more. We take pride in showcasing the work of some of Canada’s top investigators and providing our readers with the latest relevant evidence-based research, and on being the primary repository for major guidelines and other important practice recommendations. Our long-term vision is to become an essential destination for urology-based research, education, and advocacy for both physicians and patients, and to act as a springboard for discussions within the urologic community.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
